P-44 TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH CONTROVERSIAL INDICATION
Introduction: Transarterial chemoembolization (TACE) is considered the therapy of choice in patients with intermediate stage hepatocellular carcinoma (HCC) who are not candidates for surgical resection or tumor ablation. There are discrepancies in the American and European consensus on the treatment...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | Annals of Hepatology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268121001071 |
id |
doaj-35ec51ee0d5440889e8f087861990e34 |
---|---|
record_format |
Article |
spelling |
doaj-35ec51ee0d5440889e8f087861990e342021-09-29T04:23:44ZengElsevierAnnals of Hepatology1665-26812021-09-0124100408P-44 TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH CONTROVERSIAL INDICATIONAlejandra Domínguez0Gabriel Puelma1Marcelo Salinas2Máximo Cattaneo3Alvaro Urzúa4Juan Pablo Roblero5Jaime Poniachik6Sección Gastroenterología, Departamento de Medicina Interna, Santiago, ChileHospital Clínico de la Universidad de Chile, Santiago, ChileSección Gastroenterología, Departamento de Medicina Interna, Santiago, ChileSección Gastroenterología, Departamento de Medicina Interna, Santiago, ChileSección Gastroenterología, Departamento de Medicina Interna, Santiago, ChileSección Gastroenterología, Departamento de Medicina Interna, Santiago, ChileSección Gastroenterología, Departamento de Medicina Interna, Santiago, ChileIntroduction: Transarterial chemoembolization (TACE) is considered the therapy of choice in patients with intermediate stage hepatocellular carcinoma (HCC) who are not candidates for surgical resection or tumor ablation. There are discrepancies in the American and European consensus on the treatment of HCC in Child B stage patients, given it is associated with an increased risk of liver failure and death. Objective: To describe the experience of a University Center in the management of patients with HCC and cirrhosis Child B. Methods: Observational, retrospective study. 25 patients were included. Sociodemographic variables, aetiology of cirrhosis, HCC stage, treatment and associated decompensations were included. The analysis was carried out with descriptive statistics. Results: Of the patients, 14 women, 24% with MELD-Na ≥ 15 (15-20). 44% NASH, 20% HCV infection. 56% and 34% in stage A and B of Barcelona. 32% within the Milan criteria and 25% within San Francisco. After the TACE, 16% presented immediate complications, without associated mortality. At 6 months of follow-up, 36% presented an increase in MELD-Na by (2-6) points, 32% presented or increased ascites, 12% progressed to Child C. Survival at 6 months after chemoembolization was 76%. Conclusion: TACE was a safe procedure in patients with Child B, in terms of immediate complications, however, a considerable percentage presented deterioration of liver function at 6 months of follow up. This therapy in Child B patients should be evaluated individually case by case.http://www.sciencedirect.com/science/article/pii/S1665268121001071 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alejandra Domínguez Gabriel Puelma Marcelo Salinas Máximo Cattaneo Alvaro Urzúa Juan Pablo Roblero Jaime Poniachik |
spellingShingle |
Alejandra Domínguez Gabriel Puelma Marcelo Salinas Máximo Cattaneo Alvaro Urzúa Juan Pablo Roblero Jaime Poniachik P-44 TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH CONTROVERSIAL INDICATION Annals of Hepatology |
author_facet |
Alejandra Domínguez Gabriel Puelma Marcelo Salinas Máximo Cattaneo Alvaro Urzúa Juan Pablo Roblero Jaime Poniachik |
author_sort |
Alejandra Domínguez |
title |
P-44 TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH CONTROVERSIAL INDICATION |
title_short |
P-44 TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH CONTROVERSIAL INDICATION |
title_full |
P-44 TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH CONTROVERSIAL INDICATION |
title_fullStr |
P-44 TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH CONTROVERSIAL INDICATION |
title_full_unstemmed |
P-44 TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH CONTROVERSIAL INDICATION |
title_sort |
p-44 transarterial chemoembolization in patients with controversial indication |
publisher |
Elsevier |
series |
Annals of Hepatology |
issn |
1665-2681 |
publishDate |
2021-09-01 |
description |
Introduction: Transarterial chemoembolization (TACE) is considered the therapy of choice in patients with intermediate stage hepatocellular carcinoma (HCC) who are not candidates for surgical resection or tumor ablation. There are discrepancies in the American and European consensus on the treatment of HCC in Child B stage patients, given it is associated with an increased risk of liver failure and death. Objective: To describe the experience of a University Center in the management of patients with HCC and cirrhosis Child B. Methods: Observational, retrospective study. 25 patients were included. Sociodemographic variables, aetiology of cirrhosis, HCC stage, treatment and associated decompensations were included. The analysis was carried out with descriptive statistics. Results: Of the patients, 14 women, 24% with MELD-Na ≥ 15 (15-20). 44% NASH, 20% HCV infection. 56% and 34% in stage A and B of Barcelona. 32% within the Milan criteria and 25% within San Francisco. After the TACE, 16% presented immediate complications, without associated mortality. At 6 months of follow-up, 36% presented an increase in MELD-Na by (2-6) points, 32% presented or increased ascites, 12% progressed to Child C. Survival at 6 months after chemoembolization was 76%. Conclusion: TACE was a safe procedure in patients with Child B, in terms of immediate complications, however, a considerable percentage presented deterioration of liver function at 6 months of follow up. This therapy in Child B patients should be evaluated individually case by case. |
url |
http://www.sciencedirect.com/science/article/pii/S1665268121001071 |
work_keys_str_mv |
AT alejandradominguez p44transarterialchemoembolizationinpatientswithcontroversialindication AT gabrielpuelma p44transarterialchemoembolizationinpatientswithcontroversialindication AT marcelosalinas p44transarterialchemoembolizationinpatientswithcontroversialindication AT maximocattaneo p44transarterialchemoembolizationinpatientswithcontroversialindication AT alvarourzua p44transarterialchemoembolizationinpatientswithcontroversialindication AT juanpabloroblero p44transarterialchemoembolizationinpatientswithcontroversialindication AT jaimeponiachik p44transarterialchemoembolizationinpatientswithcontroversialindication |
_version_ |
1716864848132833280 |